Trial of oral miltefosine for visceral leishmaniasis

@article{Sundar1998TrialOO,
  title={Trial of oral miltefosine for visceral leishmaniasis},
  author={S. Sundar and F. Rosenkaimer and M. Makharia and A. Goyal and H. Murray},
  journal={The Lancet},
  year={1998},
  volume={352},
  pages={1821-1823}
}
BACKGROUND There is no effective oral treatment for visceral leishmaniasis (kala-azar), a disseminated intracellular protozoal infection that occurs worldwide. Miltefosine, an alkyl phospholipid developed as an oral antineoplastic agent, is active against visceral infection in animal models. We tested safety, tolerance, and efficacy of miltefosine in kala-azar. METHODS Oral doses of miltefosine were given to six groups of five Indian men for 28 days: 50 mg every second day (group 1), 100 mg… Expand
220 Citations

Paper Mentions

Interventional Clinical Trial
Cutaneous leishmaniasis (CL) is a worldwide disease, endemic in 88 countries, that has shown an increasing incidence the last two decades. It is estimated that in 2005, about of 20,000… Expand
ConditionsCutaneous Leishmaniasis
InterventionDevice, Drug
Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.
  • 435
Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent.
  • J. Soto, J. Toledo, +6 authors J. Berman
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2001
  • 186
  • PDF
Oral miltefosine for Indian visceral leishmaniasis.
  • 660
  • PDF
Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
  • 77
Oral miltefosine for the treatment of Indian visceral leishmaniasis.
  • 101
Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India.
  • 142
  • PDF
Miltefosine: oral treatment of leishmaniasis
  • 61
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 16 REFERENCES
Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome).
  • 159
  • PDF
Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice.
  • 188
  • PDF
Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis.
  • J. Sherwood, G. Gachihi, +7 authors J. Mbugua
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1994
  • 86
Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years.
  • J. Berman
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1997
  • 777
  • PDF
...
1
2
...